We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
RegeneRX Biopharmaceuticals Inc (CE) | USOTC:RGRX | OTCMarkets | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.0014 | 0.0014 | 0.0014 | 0.0014 | 100 | 01:00:00 |
1. Name and Address of Reporting Person * Essetifin SPA | 2. Issuer Name and Ticker or Trading Symbol REGENERX BIOPHARMACEUTICALS INC [ RGRX ] |
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director __X__ 10% Owner _____ Officer (give title below) _____ Other (specify below) |
3. Date of Earliest Transaction
(MM/DD/YYYY)
| ||
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
___ Form filed by One Reporting Person
_ X _ Form filed by More than One Reporting Person |
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | ||||||||||
1.Title of Security (Instr. 3) | 2. Trans. Date | 2A. Deemed Execution Date, if any |
3. Trans. Code (Instr. 8) |
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) |
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |||
Code | V | Amount | (A) or (D) | Price | ||||||
Common Stock | 34989080 | D (7) |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||||||||||
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | ||||
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||||||
Convertible Promissory Note (right to buy) | $0.12 (1)(2) | 2/26/2019 | (1)(2) | Common Stock | (1)(2) | $500000 (1)(2) | D (7) | ||||||||
Common Stock Warrant (right to buy) | $0.18 (1)(3) | 8/26/2019 | 2/26/2024 | Common Stock | 3125000 (1)(3) | 3125000 (1)(3) | D (7) | ||||||||
Convertible Promissory Note (right to buy) | $0.12 (1)(2) | 5/13/2019 | (1)(2) | Common Stock | (1)(2) | $500000 (1)(2) | D (7) | ||||||||
Common Stock Warrant (right to buy) | $0.18 (1)(3) | 11/13/2019 | 3/1/2024 | Common Stock | 3125000 (1)(3) | 3125000 (1)(3) | D (7) | ||||||||
Convertible Promissory Note (right to buy) | (4)(5) | 10/15/2020 | P | $400000 (4)(5) | 10/15/2020 | (4)(5) | Common Stock | (4)(5) | $400000 (4)(5) | $400000 (4)(5) | D (7) | ||||
Common Stock Warrant (right to buy) | $0.45 (4)(6) | 10/15/2020 | J | 835189 (4)(6) | 4/15/2021 | 10/15/2025 | Common Stock | 835189 (4)(6) | (4)(6) | 835189 (4)(6) | D (7) |
Remarks: Exhibit List: Exhibit 99.1 - Joint Filers' Signatures |
Reporting Owners | |||||
Reporting Owner Name / Address | |||||
Director | 10% Owner | Officer | Other | ||
Essetifin SPA VIA SUDAFRICA, 20 ROME, L6 00144 | X | ||||
CAVAZZA PAOLO VIA TESSERETE, 10 LUGANO, V8 00000 | X | ||||
Cavazza Enrico VIA SUDAFRICA, 20 ROME, L6 00144 | X | ||||
Cavazza Francesca VIA SUDAFRICA, 20 ROME, L6 00144 | X | ||||
Cavazza Silvia VIA SUDAFRICA, 20 ROME, L6 00144 | X | ||||
Cavazza Preta Martina VIA SUDAFRICA, 20 ROME, L6 00144 | X |
Signatures | ||
Essetifin S.p.A. By: /s/ Marino Zigrossi | 10/16/2020 | |
**Signature of Reporting Person | Date | |
/s/ Marino Zigrossi for Enrico Cavazza by power of attorney | 10/16/2020 | |
**Signature of Reporting Person | Date | |
/s/ Marino Zigrossi for Francesca Cavazza by power of attorney | 10/16/2020 | |
**Signature of Reporting Person | Date | |
/s/ Marino Zigrossi for Silvia Cavazza by power of attorney | 10/16/2020 | |
**Signature of Reporting Person | Date | |
/s/ Marino Zigrossi for Martina Cavazza Preta by power of attorney | 10/16/2020 | |
**Signature of Reporting Person | Date | |
/s/ Fabio Poma for Paolo Cavazza by power of attorney | 10/16/2020 | |
**Signature of Reporting Person | Date |
1 Year RegeneRX Biopharmaceutic... (CE) Chart |
1 Month RegeneRX Biopharmaceutic... (CE) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions